Cargando…
A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
BACKGROUND: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). METHODS: Primary endpoint was SSO requiring intervention...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689054/ https://www.ncbi.nlm.nih.gov/pubmed/34976385 http://dx.doi.org/10.1016/j.amsu.2021.103156 |
_version_ | 1784618473405546496 |
---|---|
author | Hope, William W. El-Ghazzawy, Adel G. Winterstein, Brad A. Blatnik, Jeffrey A. Davis, S. Scott Greenberg, Jacob A. Sanchez, Noel C. Pauli, Eric M. Tseng, Daniel M. LeBlanc, Karl A. Roberts, Kurt E. Bower, Curtis E. Parra-Davila, Eduardo Roth, J. Scott Deeken, Corey R. Smith, Eric F. |
author_facet | Hope, William W. El-Ghazzawy, Adel G. Winterstein, Brad A. Blatnik, Jeffrey A. Davis, S. Scott Greenberg, Jacob A. Sanchez, Noel C. Pauli, Eric M. Tseng, Daniel M. LeBlanc, Karl A. Roberts, Kurt E. Bower, Curtis E. Parra-Davila, Eduardo Roth, J. Scott Deeken, Corey R. Smith, Eric F. |
author_sort | Hope, William W. |
collection | PubMed |
description | BACKGROUND: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). METHODS: Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and Quality of Life at 1, 3, 6, 12, 18, and 24-months. RESULTS: 120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m(2) received P4HB-ST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%), diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%), hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm(2), mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) device-related adverse events (excluding recurrence). CONCLUSION: P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high in defects ≥7.1 cm(2) (43.3%) compared to defects <7.1 cm(2) (18.6%). Thus, in LVIHR, P4HB-ST may be better suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger defects until additional studies can further investigate outcomes. |
format | Online Article Text |
id | pubmed-8689054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86890542021-12-30 A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) Hope, William W. El-Ghazzawy, Adel G. Winterstein, Brad A. Blatnik, Jeffrey A. Davis, S. Scott Greenberg, Jacob A. Sanchez, Noel C. Pauli, Eric M. Tseng, Daniel M. LeBlanc, Karl A. Roberts, Kurt E. Bower, Curtis E. Parra-Davila, Eduardo Roth, J. Scott Deeken, Corey R. Smith, Eric F. Ann Med Surg (Lond) Cohort Study BACKGROUND: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). METHODS: Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and Quality of Life at 1, 3, 6, 12, 18, and 24-months. RESULTS: 120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m(2) received P4HB-ST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%), diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%), hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm(2), mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) device-related adverse events (excluding recurrence). CONCLUSION: P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high in defects ≥7.1 cm(2) (43.3%) compared to defects <7.1 cm(2) (18.6%). Thus, in LVIHR, P4HB-ST may be better suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger defects until additional studies can further investigate outcomes. Elsevier 2021-12-06 /pmc/articles/PMC8689054/ /pubmed/34976385 http://dx.doi.org/10.1016/j.amsu.2021.103156 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Cohort Study Hope, William W. El-Ghazzawy, Adel G. Winterstein, Brad A. Blatnik, Jeffrey A. Davis, S. Scott Greenberg, Jacob A. Sanchez, Noel C. Pauli, Eric M. Tseng, Daniel M. LeBlanc, Karl A. Roberts, Kurt E. Bower, Curtis E. Parra-Davila, Eduardo Roth, J. Scott Deeken, Corey R. Smith, Eric F. A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) |
title | A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) |
title_full | A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) |
title_fullStr | A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) |
title_full_unstemmed | A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) |
title_short | A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) |
title_sort | prospective, multicenter trial of a long-term bioabsorbable mesh with sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (atlas trial) |
topic | Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689054/ https://www.ncbi.nlm.nih.gov/pubmed/34976385 http://dx.doi.org/10.1016/j.amsu.2021.103156 |
work_keys_str_mv | AT hopewilliamw aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT elghazzawyadelg aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT wintersteinbrada aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT blatnikjeffreya aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT davissscott aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT greenbergjacoba aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT sancheznoelc aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT pauliericm aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT tsengdanielm aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT leblanckarla aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT robertskurte aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT bowercurtise aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT parradavilaeduardo aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT rothjscott aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT deekencoreyr aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT smithericf aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT hopewilliamw prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT elghazzawyadelg prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT wintersteinbrada prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT blatnikjeffreya prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT davissscott prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT greenbergjacoba prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT sancheznoelc prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT pauliericm prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT tsengdanielm prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT leblanckarla prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT robertskurte prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT bowercurtise prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT parradavilaeduardo prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT rothjscott prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT deekencoreyr prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial AT smithericf prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial |